{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T20:33:56Z","timestamp":1777149236429,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Balnaves Foundation\/Sydney Medical School Kickstart Grant"},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1037903"],"award-info":[{"award-number":["1037903"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NSW DOH CV Research Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Colchicine inhibits coronary and cerebrovascular events in patients with coronary artery disease (CAD), and although known to have anti-inflammatory properties, its mechanisms of action are incompletely understood. In this study, we investigated the effects of colchicine on platelet activation with a particular focus on its effects on activation via the collagen glycoprotein (GP)VI receptor, P2Y<jats:sub>12<\/jats:sub> receptor, and procoagulant platelet formation. Therapeutic concentrations of colchicine in vitro (equivalent to plasma levels) significantly decreased platelet aggregation in whole blood and in platelet rich plasma in response to collagen (multiplate aggregometry) and reduced reactive oxygen species (ROS) generation (H<jats:sub>2<\/jats:sub>DCF-DA, flow cytometry) in response to GPVI stimulation with collagen related peptide-XL (CRP-XL, GPVI specific agonist). Other platelet activation pathways including P-selectin expression, GPIIb\/IIIa conformational change and procoagulant platelet formation (GSAO<jats:sup>+<\/jats:sup>\/CD62P<jats:sup>+<\/jats:sup>) (flow cytometry) were inhibited with higher concentrations of colchicine known to inhibit microtubule depolymerization. Pathway specific mechanisms of action of colchicine on platelets, including modulation of the GPVI receptor pathway at low concentrations, may contribute to its protective role in CAD.<\/jats:p>","DOI":"10.1038\/s41598-021-91409-7","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T10:06:06Z","timestamp":1623060366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Colchicine inhibits ROS generation in response to glycoprotein VI stimulation"],"prefix":"10.1038","volume":"11","author":[{"given":"G. J.","family":"Pennings","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J.","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Traini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Kritharides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"91409_CR1","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.jacc.2013.08.726","volume":"62","author":"S Deftereos","year":"2013","unstructured":"Deftereos, S. et al. Colchicine and the heart: Pushing the envelope. J. Am. Coll. Cardiol. 62, 1817\u20131825. https:\/\/doi.org\/10.1016\/j.jacc.2013.08.726 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"91409_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.tcm.2014.09.011","volume":"25","author":"M Imazio","year":"2015","unstructured":"Imazio, M. Colchicine for pericarditis. Trends Cardiovasc. Med. 25, 129\u2013136. https:\/\/doi.org\/10.1016\/j.tcm.2014.09.011 (2015).","journal-title":"Trends Cardiovasc. Med."},{"key":"91409_CR3","doi-asserted-by":"publisher","first-page":"e0237665","DOI":"10.1371\/journal.pone.0237665","volume":"15","author":"ATL Fiolet","year":"2020","unstructured":"Fiolet, A. T. L. et al. Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PLoS\u00a0One 15, e0237665. https:\/\/doi.org\/10.1371\/journal.pone.0237665 (2020).","journal-title":"PLoS\u00a0One"},{"key":"91409_CR4","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/ene.14198","volume":"27","author":"AH Katsanos","year":"2020","unstructured":"Katsanos, A. H. et al. Colchicine for stroke prevention in patients with coronary artery disease: A systematic review and meta-analysis. Eur. J. Neurol. 27, 1035\u20131038. https:\/\/doi.org\/10.1111\/ene.14198 (2020).","journal-title":"Eur. J. Neurol."},{"key":"91409_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11883-013-0391-z","volume":"16","author":"SM Nidorf","year":"2014","unstructured":"Nidorf, S. M., Eikelboom, J. W. & Thompson, P. L. Colchicine for secondary prevention of cardiovascular disease. Curr. Atheroscler. Rep. 16, 391. https:\/\/doi.org\/10.1007\/s11883-013-0391-z (2014).","journal-title":"Curr. Atheroscler. Rep."},{"key":"91409_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/1755-5922.12226","volume":"35","author":"N Papageorgiou","year":"2017","unstructured":"Papageorgiou, N., Briasoulis, A., Lazaros, G., Imazio, M. & Tousoulis, D. Colchicine for prevention and treatment of cardiac diseases: A meta-analysis. Cardiovasc. Ther. 35, 10\u201318. https:\/\/doi.org\/10.1111\/1755-5922.12226 (2017).","journal-title":"Cardiovasc. Ther."},{"key":"91409_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/1573403X12666161014094159","volume":"13","author":"G-M Tan","year":"2017","unstructured":"Tan, G.-M. & Yan, B. P. What\u2019s old is new again\u2014A review of the current evidence of colchicine in cardiovascular medicine. Curr. Cardiol. Rev. 13, 130\u2013138. https:\/\/doi.org\/10.2174\/1573403X12666161014094159 (2017).","journal-title":"Curr. Cardiol. Rev."},{"key":"91409_CR8","doi-asserted-by":"publisher","first-page":"e002128","DOI":"10.1161\/JAHA.115.002128","volume":"4","author":"GJ Martinez","year":"2015","unstructured":"Martinez, G. J. et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J. Am. Heart Assoc. 4, e002128. https:\/\/doi.org\/10.1161\/JAHA.115.002128 (2015).","journal-title":"J. Am. Heart Assoc."},{"key":"91409_CR9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A. & Thompson, P. L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 61, 404\u2013410. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.027 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"91409_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ahj.2019.09.011","volume":"218","author":"SM Nidorf","year":"2019","unstructured":"Nidorf, S. M. et al. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. Am. Heart J. 218, 46\u201356. https:\/\/doi.org\/10.1016\/j.ahj.2019.09.011 (2019).","journal-title":"Am. Heart J."},{"key":"91409_CR11","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.120.050560","volume":"142","author":"TSJ Opstal","year":"2020","unstructured":"Opstal, T. S. J. et al. Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: A LoDoCo2 proteomic substudy. Circulation 142, 1996\u20131998. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050560 (2020).","journal-title":"Circulation"},{"key":"91409_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/clpt.1993.161","volume":"54","author":"ON Chappey","year":"1993","unstructured":"Chappey, O. N. et al. Colchicine disposition in human leukocytes after single and multiple oral administration. Clin. Pharmacol. Ther. 54, 360\u2013367. https:\/\/doi.org\/10.1038\/clpt.1993.161 (1993).","journal-title":"Clin. Pharmacol. Ther."},{"key":"91409_CR13","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/j.1552-4604.1996.tb04753.x","volume":"36","author":"GM Ferron","year":"1996","unstructured":"Ferron, G. M., Rochdi, M., Jusko, W. J. & Scherrmann, J. M. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J. Clin. Pharmacol. 36, 874\u2013883. https:\/\/doi.org\/10.1002\/j.1552-4604.1996.tb04753.x (1996).","journal-title":"J. Clin. Pharmacol."},{"key":"91409_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1160\/TH07-01-0061","volume":"98","author":"A Bouaziz","year":"2007","unstructured":"Bouaziz, A. et al. Tyrosine phosphorylation\/dephosphorylation balance is involved in thrombin-evoked microtubular reorganisation in human platelets. Thromb. Haemost. 98, 375\u2013384. https:\/\/doi.org\/10.1160\/TH07-01-0061 (2007).","journal-title":"Thromb. Haemost."},{"key":"91409_CR15","first-page":"281","volume":"53","author":"JG White","year":"1968","unstructured":"White, J. G. Effects of colchicine and Vinca alkaloids on human platelets. I. Influence on platelet microtubules and contractile function. Am. J. Pathol. 53, 281\u2013291 (1968).","journal-title":"Am. J. Pathol."},{"key":"91409_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241. https:\/\/doi.org\/10.1038\/nature04516 (2006).","journal-title":"Nature"},{"key":"91409_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1172\/JCI118147","volume":"96","author":"BN Cronstein","year":"1995","unstructured":"Cronstein, B. N. et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J. Clin. Investig. 96, 994\u20131002. https:\/\/doi.org\/10.1172\/JCI118147 (1995).","journal-title":"J. Clin. Investig."},{"key":"91409_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00232-011-9404-4","volume":"244","author":"S Korkmaz","year":"2011","unstructured":"Korkmaz, S. et al. Colchicine modulates oxidative stress in serum and neutrophil of patients with Behcet disease through regulation of Ca(2)(+) release and antioxidant system. J. Membr. Biol. 244, 113\u2013120. https:\/\/doi.org\/10.1007\/s00232-011-9404-4 (2011).","journal-title":"J. Membr. Biol."},{"key":"91409_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/fcvm.2019.00132","volume":"6","author":"H Lebas","year":"2019","unstructured":"Lebas, H., Yahiaoui, K., Martos, R. & Boulaftali, Y. Platelets are at the nexus of vascular diseases. Front. Cardiovasc. Med. 6, 132. https:\/\/doi.org\/10.3389\/fcvm.2019.00132 (2019).","journal-title":"Front. Cardiovasc. Med."},{"key":"91409_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fimmu.2015.00098","volume":"6","author":"HM Nording","year":"2015","unstructured":"Nording, H. M., Seizer, P. & Langer, H. F. Platelets in inflammation and atherogenesis. Front. Immunol. 6, 98. https:\/\/doi.org\/10.3389\/fimmu.2015.00098 (2015).","journal-title":"Front. Immunol."},{"key":"91409_CR21","first-page":"448","volume":"29","author":"RA Hardwick","year":"1983","unstructured":"Hardwick, R. A., Gritsman, H. N., Stromberg, R. R. & Friedman, L. I. The biochemical mechanisms of shear-induced platelet aggregation. Trans. Am. Soc. Artif. Intern. Organs 29, 448\u2013453 (1983).","journal-title":"Trans. Am. Soc. Artif. Intern. Organs"},{"key":"91409_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1042\/bj1780449","volume":"178","author":"A Ribbi-Jaffe","year":"1979","unstructured":"Ribbi-Jaffe, A. & Apitz-Castro, R. The effect of colchicine on human blood platelets under conditions of short-term incubation. Biochem. J. 178, 449\u2013454 (1979).","journal-title":"Biochem. J."},{"key":"91409_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1113\/jphysiol.1971.sp009424","volume":"214","author":"JM Sneddon","year":"1971","unstructured":"Sneddon, J. M. Effect of mitosis inhibitors on blood platelet microtubules and aggregation. J. Physiol. 214, 145\u2013158. https:\/\/doi.org\/10.1113\/jphysiol.1971.sp009424 (1971).","journal-title":"J. Physiol."},{"key":"91409_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/s0368-1319(69)80012-8","volume":"10","author":"GD Soppitt","year":"1969","unstructured":"Soppitt, G. D. & Mitchell, J. R. The effect of colchicine on human platelet behaviour. J. Atheroscler. Res. 10, 247\u2013252. https:\/\/doi.org\/10.1016\/s0368-1319(69)80012-8 (1969).","journal-title":"J. Atheroscler. Res."},{"key":"91409_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1172\/JCI109855","volume":"66","author":"D Menche","year":"1980","unstructured":"Menche, D., Israel, A. & Karpatkin, S. Platelets and microtubules. Effect of colchicine and D2O on platelet aggregation and release induced by calcium ionophore A23187. J. Clin. Investig. 66, 284\u2013291. https:\/\/doi.org\/10.1172\/JCI109855 (1980).","journal-title":"J. Clin. Investig."},{"key":"91409_CR26","first-page":"467","volume":"54","author":"JG White","year":"1969","unstructured":"White, J. G. Effects of colchicine and vinca alkaloids on human platelets. 3. Influence on primary internal contraction and secondary aggregation. Am. J. Pathol. 54, 467\u2013478 (1969).","journal-title":"Am. J. Pathol."},{"key":"91409_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s10753-015-0237-7","volume":"39","author":"B Shah","year":"2016","unstructured":"Shah, B. et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: A pilot study in healthy subjects. Inflammation 39, 182\u2013189. https:\/\/doi.org\/10.1007\/s10753-015-0237-7 (2016).","journal-title":"Inflammation"},{"key":"91409_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.vph.2018.09.004","volume":"111","author":"G Cimmino","year":"2018","unstructured":"Cimmino, G. et al. Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascul. Pharmacol. 111, 62\u201370. https:\/\/doi.org\/10.1016\/j.vph.2018.09.004 (2018).","journal-title":"Vascul. Pharmacol."},{"key":"91409_CR29","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11239-020-02121-8","volume":"50","author":"P Cirillo","year":"2020","unstructured":"Cirillo, P. et al. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. J. Thromb. Thrombolysis 50, 468\u2013472. https:\/\/doi.org\/10.1007\/s11239-020-02121-8 (2020).","journal-title":"J. Thromb. Thrombolysis"},{"key":"91409_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1055\/s-0038-1636915","volume":"118","author":"CJ Reddel","year":"2018","unstructured":"Reddel, C. J., Pennings, G. J., Curnow, J. L., Chen, V. M. & Kritharides, L. Procoagulant effects of low-level platelet activation and its inhibition by colchicine. Thromb. Haemost. 118, 723\u2013733. https:\/\/doi.org\/10.1055\/s-0038-1636915 (2018).","journal-title":"Thromb. Haemost."},{"key":"91409_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2010-04-278812","volume":"117","author":"AS Yong","year":"2011","unstructured":"Yong, A. S. et al. Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel. Blood 117, 11\u201320. https:\/\/doi.org\/10.1182\/blood-2010-04-278812 (2011).","journal-title":"Blood"},{"key":"91409_CR32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1083\/jcb.200801146","volume":"182","author":"TA Springer","year":"2008","unstructured":"Springer, T. A., Zhu, J. & Xiao, T. Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3. J. Cell Biol. 182, 791\u2013800. https:\/\/doi.org\/10.1083\/jcb.200801146 (2008).","journal-title":"J. Cell Biol."},{"key":"91409_CR33","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1182\/blood-2015-08-663005","volume":"126","author":"VM Hua","year":"2015","unstructured":"Hua, V. M. et al. Necrotic platelets provide a procoagulant surface during thrombosis. Blood 126, 2852\u20132862. https:\/\/doi.org\/10.1182\/blood-2015-08-663005 (2015).","journal-title":"Blood"},{"key":"91409_CR34","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/jth.14008","volume":"16","author":"L Pasalic","year":"2018","unstructured":"Pasalic, L. et al. Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response. J. Thromb. Haemost. 16, 1198\u20131210. https:\/\/doi.org\/10.1111\/jth.14008 (2018).","journal-title":"J. Thromb. Haemost."},{"key":"91409_CR35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131. https:\/\/doi.org\/10.1056\/NEJMoa1707914 (2017).","journal-title":"N. Engl. J. Med."},{"key":"91409_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/JBM.S39220","volume":"5","author":"RK Andrews","year":"2014","unstructured":"Andrews, R. K., Arthur, J. F. & Gardiner, E. E. Targeting GPVI as a novel antithrombotic strategy. J. Blood Med. 5, 59\u201368. https:\/\/doi.org\/10.2147\/JBM.S39220 (2014).","journal-title":"J. Blood Med."},{"key":"91409_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/09537104.2018.1453058","volume":"29","author":"F Mingant","year":"2018","unstructured":"Mingant, F. et al. Comparison of four methods to assess high-on platelet reactivity under P2Y12 receptor inhibitor. Platelets 29, 257\u2013264. https:\/\/doi.org\/10.1080\/09537104.2018.1453058 (2018).","journal-title":"Platelets"},{"key":"91409_CR38","doi-asserted-by":"publisher","first-page":"107630","DOI":"10.1016\/j.pharmthera.2020.107630","volume":"217","author":"O Borst","year":"2021","unstructured":"Borst, O. & Gawaz, M. Glycoprotein VI\u2014Novel target in antiplatelet medication. Pharmacol. Ther. 217, 107630. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107630 (2021).","journal-title":"Pharmacol. Ther."},{"key":"91409_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/jci122955","volume":"129","author":"J Rayes","year":"2019","unstructured":"Rayes, J., Watson, S. P. & Nieswandt, B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J. Clin. Investig. 129, 12\u201323. https:\/\/doi.org\/10.1172\/jci122955 (2019).","journal-title":"J. Clin. Investig."},{"key":"91409_CR40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/09537104.2016.1227062","volume":"28","author":"M Chatterjee","year":"2017","unstructured":"Chatterjee, M. & Gawaz, M. Clinical significance of receptor shedding-platelet GPVI as an emerging diagnostic and therapeutic tool. Platelets 28, 362\u2013371. https:\/\/doi.org\/10.1080\/09537104.2016.1227062 (2017).","journal-title":"Platelets"},{"key":"91409_CR41","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1161\/ATVBAHA.120.314301","volume":"40","author":"MU Ahmed","year":"2020","unstructured":"Ahmed, M. U. et al. Pharmacological blockade of glycoprotein VI promotes thrombus disaggregation in the absence of thrombin. Arterioscler. Thromb. Vasc. Biol. 40, 2127\u20132142. https:\/\/doi.org\/10.1161\/ATVBAHA.120.314301 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"91409_CR42","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1538-7836.2012.04734.x","volume":"10","author":"JF Arthur","year":"2012","unstructured":"Arthur, J. F. et al. ITAM receptor-mediated generation of reactive oxygen species in human platelets occurs via Syk-dependent and Syk-independent pathways. J. Thromb. Haemost. 10, 1133\u20131141. https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04734.x (2012).","journal-title":"J. Thromb. Haemost."},{"key":"91409_CR43","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1111\/j.1538-7836.2007.02590.x","volume":"5","author":"EE Gardiner","year":"2007","unstructured":"Gardiner, E. E. et al. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J. Thromb. Haemost. 5, 1530\u20131537. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02590.x (2007).","journal-title":"J. Thromb. Haemost."},{"key":"91409_CR44","doi-asserted-by":"publisher","first-page":"e71193","DOI":"10.1371\/journal.pone.0071193","volume":"8","author":"M Ungerer","year":"2013","unstructured":"Ungerer, M. et al. The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times. PLoS ONE 8, e71193. https:\/\/doi.org\/10.1371\/journal.pone.0071193 (2013).","journal-title":"PLoS ONE"},{"key":"91409_CR45","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1042\/BJ20031430","volume":"378","author":"K Suzuki-Inoue","year":"2004","unstructured":"Suzuki-Inoue, K. et al. Glycoproteins VI and Ib-IX-V stimulate tyrosine phosphorylation of tyrosine kinase Syk and phospholipase Cgamma2 at distinct sites. Biochem. J. 378, 1023\u20131029. https:\/\/doi.org\/10.1042\/BJ20031430 (2004).","journal-title":"Biochem. J."},{"key":"91409_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1172\/JCI111931","volume":"76","author":"BS Coller","year":"1985","unstructured":"Coller, B. S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and\/or microenvironment of the platelet glycoprotein IIb\/IIIa complex. J. Clin. Investig. 76, 101\u2013108. https:\/\/doi.org\/10.1172\/JCI111931 (1985).","journal-title":"J. Clin. Investig."},{"key":"91409_CR47","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood.V68.3.783.783","volume":"68","author":"BS Coller","year":"1986","unstructured":"Coller, B. S., Folts, J. D., Scudder, L. E. & Smith, S. R. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb\/IIIa receptor in an experimental animal model. Blood 68, 783\u2013786. https:\/\/doi.org\/10.1182\/blood.V68.3.783.783 (1986).","journal-title":"Blood"},{"key":"91409_CR48","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1182\/blood.V66.6.1456.1456","volume":"66","author":"BS Coller","year":"1985","unstructured":"Coller, B. S. & Scudder, L. E. Inhibition of dog platelet function by in vivo infusion of F(ab\u2019)2 fragments of a monoclonal antibody to the platelet glycoprotein IIb\/IIIa receptor. Blood 66, 1456\u20131459. https:\/\/doi.org\/10.1182\/blood.V66.6.1456.1456 (1985).","journal-title":"Blood"},{"key":"91409_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s0002-9149(96)00490-0","volume":"78","author":"JE Tcheng","year":"1996","unstructured":"Tcheng, J. E. Glycoprotein IIb\/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am. J. Cardiol. 78, 35\u201340. https:\/\/doi.org\/10.1016\/s0002-9149(96)00490-0 (1996).","journal-title":"Am. J. Cardiol."},{"key":"91409_CR50","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/00003495-199958040-00003","volume":"58","author":"DF Kong","year":"1999","unstructured":"Kong, D. F. & Califf, R. M. Glycoprotein IIb\/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: A review of trial reports. Drugs 58, 609\u2013620. https:\/\/doi.org\/10.2165\/00003495-199958040-00003 (1999).","journal-title":"Drugs"},{"key":"91409_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1753944713487781","volume":"7","author":"A Muniz-Lozano","year":"2013","unstructured":"Muniz-Lozano, A., Rollini, F., Franchi, F. & Angiolillo, D. J. Update on platelet glycoprotein IIb\/IIIa inhibitors: Recommendations for clinical practice. Ther. Adv. Cardiovasc. Dis. 7, 197\u2013213. https:\/\/doi.org\/10.1177\/1753944713487781 (2013).","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"91409_CR52","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/00005344-200208000-00015","volume":"40","author":"A Caron","year":"2002","unstructured":"Caron, A., Theoret, J. F., Mousa, S. A. & Merhi, Y. Anti-platelet effects of GPIIb\/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils. J. Cardiovasc. Pharmacol. 40, 296\u2013306. https:\/\/doi.org\/10.1097\/00005344-200208000-00015 (2002).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"91409_CR53","first-page":"429","volume":"32","author":"A Sabouraud","year":"1994","unstructured":"Sabouraud, A., Chappey, O., Dupin, T. & Scherrmann, J. M. Binding of colchicine and thiocolchicoside to human serum proteins and blood cells. Int. J. Clin. Pharmacol. Ther. 32, 429\u2013432 (1994).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"91409_CR54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1055\/s-0034-1544002","volume":"41","author":"VM Hua","year":"2015","unstructured":"Hua, V. M. & Chen, V. M. Procoagulant platelets and the pathways leading to cell death. Semin. Thromb. Hemost. 41, 405\u2013412. https:\/\/doi.org\/10.1055\/s-0034-1544002 (2015).","journal-title":"Semin. Thromb. Hemost."},{"key":"91409_CR55","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.2515","volume":"17","author":"SP Jackson","year":"2011","unstructured":"Jackson, S. P. Arterial thrombosis\u2013insidious, unpredictable and deadly. Nat. Med. 17, 1423\u20131436. https:\/\/doi.org\/10.1038\/nm.2515 (2011).","journal-title":"Nat. Med."},{"key":"91409_CR56","doi-asserted-by":"publisher","first-page":"e969","DOI":"10.1038\/cddis.2013.495","volume":"4","author":"MT Harper","year":"2013","unstructured":"Harper, M. T. & Poole, A. W. Chloride channels are necessary for full platelet phosphatidylserine exposure and procoagulant activity. Cell Death Dis. 4, e969. https:\/\/doi.org\/10.1038\/cddis.2013.495 (2013).","journal-title":"Cell Death Dis."},{"key":"91409_CR57","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1182\/blood-2006-01-009613","volume":"108","author":"JL Wolfs","year":"2006","unstructured":"Wolfs, J. L. et al. Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood 108, 2223\u20132228. https:\/\/doi.org\/10.1182\/blood-2006-01-009613 (2006).","journal-title":"Blood"},{"key":"91409_CR58","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1161\/CIRCULATIONAHA.114.015036","volume":"132","author":"EO Agbani","year":"2015","unstructured":"Agbani, E. O. et al. Coordinated membrane ballooning and procoagulant spreading in human platelets. Circulation 132, 1414\u20131424. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.015036 (2015).","journal-title":"Circulation"},{"key":"91409_CR59","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1538-7836.2009.03716.x","volume":"8","author":"GJ Pennings","year":"2010","unstructured":"Pennings, G. J., Yong, A. S. & Kritharides, L. Expression of EMMPRIN (CD147) on circulating platelets in vivo. J. Thromb. Haemost. 8, 472\u2013481. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03716.x (2010).","journal-title":"J. Thromb. Haemost."},{"key":"91409_CR60","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/978-1-4939-7196-1_28","volume":"1646","author":"L Pasalic","year":"2017","unstructured":"Pasalic, L. et al. Flow cytometry protocols for assessment of platelet function in whole blood. Methods Mol. Biol. 1646, 369\u2013389. https:\/\/doi.org\/10.1007\/978-1-4939-7196-1_28 (2017).","journal-title":"Methods Mol. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91409-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91409-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91409-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:17:32Z","timestamp":1670059052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91409-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91409"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91409-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11965"}}